Clinical Trial Update: Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of recombinant human erythropoietin-alfa in anemia associated with chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• Erythropoietin alfa (erythropoietin alfa)

Snippet

Sponsor: Cadila Pharnmaceuticals | Conditions: Anemia | Phase 3 | Status: COMPLETED